In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

Por Rolf, Michael G, Curwen, Jon O, Veldman-Jones, Margaret, Eberlein, Cath, Wang, Jianyan, Harmer, Alex, Hellawell, Caroline J, Braddock, Martin
Publicado no Pharmacol Res Perspect (2015)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Por Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Publicado no J Immunother Cancer (2017)